Medical Trend

Medical News and Medical Resources

Eli Lilly announces a new generation of KRAS inhibitor LY3537982

1 year ago
News

Eli Lilly announces a new generation of KRAS inhibitor LY3537982

 

 

Eli Lilly announces a new generation of KRAS inhibitor LY3537982, which is more than 10 times more active than AMG510.

RAS is the first oncogene identified in human tumors, but it has always been regarded as a “non-drugable” target. Epidemiology shows that KRAS mutations account for approximately 13% in NSCLC, approximately 3%-5% in colorectal cancer, and approximately 1%-2% in other solid tumors.

 

The fastest-growing KRAS-G12C irreversible inhibitor Sotorasib (AMG510) has submitted a marketing application at the end of last year and is expected to become the first KRAS targeted drug approved for marketing.

 

In 2019, Eli Lilly’s first KRAS G12C inhibitor, LY3499446, started clinical research, and the latter was terminated due to safety issues, and was lagging behind on the KRAS track.

Recently, Eli Lilly has made a strong comeback and announced the preclinical activity data of its new generation of KRAS G12C inhibitor LY3537982 at the AACR2021 annual meeting, which is expected to win back.

 

According to published data, LY3537982 is also a covalent KRAS-G12C inhibitor. It exhibits high target inhibitory activity in KRAS G12C mutant H23 and H358 lung cancer cell lines, with IC50 of 1.04 nM and 1.16 nM, respectively. In KRAS G12C mutant H358 cells, the inhibitory activity (IC50) of LY3537982 was at least 10 times higher than that of Sotorasib (AMG 510) and Adagrasib.

 

Eli Lilly announces a new generation of KRAS inhibitor LY3537982

 

In the KRAS-G12C mutant (PDX) model, LY3537982 showed a significant tumor growth inhibitory effect at 3-30 mg/kg QD or BID, and even made tumors completely regressed.

 

Eli Lilly announces a new generation of KRAS inhibitor LY3537982

 

 

In addition, LY3537982 showed a target occupancy rate of >90%, while the target occupancy rate of Sotorasib and Adagrasib was less than 70%.

 

Eli Lilly announces a new generation of KRAS inhibitor LY3537982

 

 

However, whether the strong target occupancy rate of LY3537982 can promote the further improvement of clinical activity remains to be confirmed by clinical studies.

 

Currently, the KRAS-G12C inhibitors in the development stage include Yifang Biologics D-1553 (Phase I/II), Novartis’ JDQ443 (Phase I/II), Genetech’s RG6330 (Phase I), Johnson & Johnson’s ARS-3248 ( Phase I), BPI-421286 (IND) of Betta Pharmaceuticals, GH35 (IND) of Qinhao Pharmaceutical, and adagrasib (Phase III) of Mirati Therapeutics.

 

Eli Lilly’s strong return has added waves to the field of KRAS inhibitors. The former may not win the final victory, and the latter is expected to become the king. The field of KRAS inhibitors is full of thorns, opportunities and hopes, and patients will ultimately benefit from it.

 

 

 

Eli Lilly announces a new generation of KRAS inhibitor LY3537982

(source:internet, reference only)

Disclaimer of medicaltrend.org

Medical News
Cancers
Drugs
Vaccines
Ask a Question

You may have missed

AbbVie’s Risankizumab for Crohn’s disease receives positive opinion from UK MHRA

2 months ago

Chinese COVID-19 vaccines are not so effective against COVID-19 and not suitable as booster shot.

2 months ago
For two consecutive days, more than 20,000 new coronavirus infections were added in a single day in Shanghai, and the epidemic showed a "rebound" trend. Since March, the cumulative number of infected people in the city has exceeded 500,000. For a large city of nearly 25 million people, that figure means 1 in 50 people is infected with Covid-19. As the number of people infected with the new crown continues to rise, a new problem has emerged - severe illness and death. 87 direct causes of death were underlying diseases or related to COVID directly? In the past week, the daily number of new deaths in Shanghai has risen significantly. Since the current round of the epidemic, there have been 87 deaths in Shanghai. Among the 87 deaths, 48 ​​were males and 39 were females, with an average age of 81.10 years and a maximum of 101 years. However, the exact age distribution was not disclosed. The above cases were all complicated with severe multi-organ underlying diseases and were in critical condition, including advanced malignant tumors, severe cardiovascular diseases (coronary heart disease, heart failure, hypertension, etc.), neurological diseases (cerebral hemorrhage, cerebral infarction, etc.) , end-stage liver cirrhosis, diabetes, uremia, etc. The immediate cause of death is the underlying disease. Studies have shown that vaccination plays an important role in preventing infected people from turning into severe disease. In these cases, the new crown vaccination rate was found to be low, and only 5 cases had been vaccinated against the new crown vaccine. " Zhao Dandan emphasized at the press conference. The above notification revealed several pieces of information: up to now, most of the 87 deaths were of advanced age and combined with severe underlying diseases, and the direct cause of death was the underlying disease; the vaccination rate was low, and only 5 cases had been vaccinated against the new crown. 500,000 cases of infection, 87 deaths, the mortality rate is really not high. However, the case fatality rate was not the only measure of the outbreak during the Omicron epidemic. As the virus mutated, Omicron's pathogenicity did drop significantly from previous waves, but it was more transmissible. "During the current epidemic, China, like other countries, has found that if medical resources are sufficient in a pandemic, it can cover the most vulnerable groups such as the elderly and those with severe underlying diseases, and provide them with sufficient medical resources and the best treatment. This will ensure the survival of high-risk groups in the epidemic to the greatest extent possible.” Only when medical resources are very sufficient can the fatality rate be maintained at a very low level. At the same time, it is the current focus of epidemic prevention to encourage all people of advanced age or those with underlying diseases to be vaccinated, and to improve the antiviral ability of vulnerable groups themselves. It is worth reminding that the direct cause of death of the 87 patients reported so far is "underlying disease", which does not mean that the new crown infection did not play a role in the death, and it should still be taken seriously. @@@@@ Laboratory indicators on the third day of hospitalization may predict the severity of the new crown While doing a good job in the treatment of critically ill patients, how to "move the threshold forward" to prevent the light from becoming serious? On April 23, a new study mentioned at the European Congress of Clinical Microbiology and Infectious Diseases suggested that "the third day of hospitalization is a turning point in disease progression in symptomatic admitted patients, and it is also the detection of whether patients will develop severe disease. an important hurdle", or be the answer to this question. Researchers from the University of Southern California found that "many patients initially require minimal levels of oxygen supplementation, such as nasal intubation, when they first present to the emergency department, but quickly progress to the need for mechanical ventilation." This means that for For some patients, the progression from infection to severe disease is very fast. To identify patients "at high risk of developing severe disease" earlier, the researchers surveyed 90 patients hospitalized with COVID-19 pneumonia between March and October 2021. Of these, the median age was 60 years, and 54% were male. Comparing the severe group and the non-severe group, it was found that on the third day of hospitalization, patients in the severe group had abnormal levels of two host proteins related to the immune response to the new crown--interferon-gamma-induced protein 10 (IP-10) and tumor necrosis factor. Apoptosis-inducing ligand (TRAIL). On the first day of admission, there were no differences in host protein levels between the two groups. But by the third day of hospitalization, the severe group had lower TRAIL levels (median: 21 vs 30 pg/mL) and higher IP-10 levels (median: 713 vs 328 pg/mL) compared with the non-critical group mL). By the fifth day, the IP-10 indicator of critically ill patients was still high. The investigators concluded that IP-10 levels ≥570 pg/mL and TRAIL levels

Shanghai COVID outbreaking: over 500K people infected and 87 deaths

2 months ago
South Korea: Over 1700 COVID-19 patients without beds and doctors desperate

More than 70% of COVID-19 patients still have sequelae after one year

2 months ago